A Study to Assess the Safety and Tolerability Profile of TR399 in Healthy Volunteers and Erectile Dysfunction Patients
NCT ID: NCT03102398
Last Updated: 2017-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
26 participants
INTERVENTIONAL
2017-03-31
2018-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The active pharmaceutical ingredient (API) of TR399 is 5% Vardenafil HCl·3H2O. Non-clinical studies have shown that the topical use of TR399 can enhance erection and sexual behavior in animal models without causing irritancy and phototoxicity.
This study is designed as a single-arm and open-label fashion in order to explore the safety and PK of TR399 in healthy volunteers, as well as the safety, PK and efficacy of TR399 in patients with ED.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single-arm and Open-label Study
TR-399 (5% Vardenafil HCl·3H2O, topical gel)
5% Vardenafil HCl·3H2O, topical gel, 2 drops (50ul, 2.5mg), q.d.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TR-399 (5% Vardenafil HCl·3H2O, topical gel)
5% Vardenafil HCl·3H2O, topical gel, 2 drops (50ul, 2.5mg), q.d.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male aged between 20\~40 years old ;
2. Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, and electrocardiogram;
3. Body mass index (BMI) between 18.5 and 27, inclusive, (BMI will be calculated as weight in kilogram \[kg\]/height in meters2 \[m2\]);
4. Clinically normal, including non-clinical significant abnormal, hematology, biochemistry and urinalysis determinations based on investigator's discretion;
5. Subject is willing and able to comply with study procedures and has signed informed consent.
6. With Erectile Function domain of the IIEF score of 25\~30
* Phase IIa
1. Male aged between 20\~70 years old ;
2. Diagnosed and confirmed ED for at least 6 months, defined as "the inability to achieve and maintain an erection of the penis sufficient to complete satisfactory sexual intercourse" by the National Institutes of Health (NIH) consensus report 1993;
3. With Erectile Function domain of the IIEF score of 13\~24;
4. Stable relationship for more than 3 months;
5. At least 4 sexual intercourse attempts at 4 different days during 4-week period prior the screening;
6. With a testosterone level ≥ 240 ng/dL (either naturally or through androgen replacement therapy);
7. Subject is willing and able to comply with study procedures and has signed informed consent.
Exclusion Criteria
1. Known or suspected allergy, hypersensitivity, or intolerance to any ingredients of study product
2. Subject who has a history or evidence of a medical condition that would expose him to an undue risk of a significant adverse event or interfere with the assessments of safety or pharmacodynamics variables during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, immune, neurological, musculoskeletal or hematological disease as determined by the clinical judgment of the investigator
3. Subject has received any investigational agent within 4 weeks prior to the screening visit
4. Subject has taken or potentially takes any prescription medication and/or over-the-counter medication from 1 week prior to the screening visit to the end of treatment (Day 15)
5. Sexual partner is a pregnant or lactating female or a female with childbearing potential not taking reliable contraceptive methods during study period Note: Acceptable contraceptive forms include
1. Established use of oral, injected or implanted hormonal methods of contraception
2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
6. Use of PDE-5 inhibitors within the last 2 weeks prior to the screening visit
7. Use of alpha blockers or nitrates within 2 weeks prior to the screening visit
8. Subject who has prolongation of QT interval \>500 ms (long QT syndrome)
9. Any of the following hematologic abnormalities:
1. Hemoglobin \< 10.0 g/dL
2. ANC \< 1,500/μL,
3. Platelets \< 75,000 /μL
10. Any of the following serum chemistry abnormalities:
1. Total bilirubin \> 1.5 × ULN,
2. gamma-GT \> 2.5 x ULN,
3. Alk-P \> 2.5 x ULN,
4. Serum albumin \< 3.0 g/dL, e Any other ≥ Grade 2 laboratory abnormality (based on CTCAE) at Screening visit (other than those listed above)
11. With history of stroke, myocardial infarction, or Coronary Artery Bypass Graft (CABG) surgery within the last 6 months prior to the screening visit
12. With history of cardiac failure (NYHA class 2 or above), unstable angina, or life-threatening arrhythmia within the last 6 months prior to the screening visit Note: NYHA = New York Heart Association
13. With blood pressures as systolic blood pressure \<90mmHg or \> 170mmHg or diastolic blood pressure \<50mmHg or \> 120 mmHg
14. History of orthostatic hypotension Note: Orthostatic hypotension is defined as a decrease in systolic blood pressure of 20 mm Hg or a decrease in diastolic blood pressure of 10 mm Hg.
15. History of syncope
16. Hereditary degenerative retinal disorders
17. History of loss of vision because of NAION (Non-arteritic anterior ischemic optic neuropathy), temporary or permanent loss of vision
18. Skin diseases, infection or cuts in penile area
19. History of psychiatric disorder
20. History of spinal cord injury
21. Use of HIV protease inhibitors (strong cytochrome P450 CYP3A4 inhibitors), such as indinavir or ritonavir within 2 weeks prior to the screening visit
22. History of left ventricular outflow obstruction, such as aortic stenosis and hypertrophic cardiomyopathy
23. With any cardiovascular disorder that is not suitable for sexual activities.
24. Use of antiarrhythmic agents class IA (such as quinidine, or procainamide) and class III (such as amiodarone or sotalol) within 2 weeks prior to the screening visit
25. With priapism, such as sickle cell anemia, multiple myeloma or leukemia
* Phase IIa
1. Known or suspected allergy, hypersensitivity, or intolerance to any ingredients of study product
2. Participated in another clinical trial and received any investigational drug within four weeks prior to the screening visit
3. Impaired hepatic function defined as alanine aminotransferase/aspartate aminotransferase (ALT/AST) or alkaline phosphatase (ALP) at least 2.5 times upper referenced limit
4. Impaired renal function defined as serum-creatinine at least 1.3 mg/dL (at least 115 mmol/L)
5. With history of stroke, myocardial infarction, or Coronary Artery Bypass Graft (CABG) surgery within the last 6 months prior to the screening visit
6. With history of cardiac failure (NYHA class 2 or above), unstable angina, or life-threatening arrhythmia within the last 6 months prior to the screening visit Note: NYHA = New York Heart Association
7. With blood pressures as systolic blood pressure \<90mmHg or \> 170mmHg or diastolic blood pressure \<50mmHg or \> 120 mmHg
8. With any uncontrolled illness or a history of any illness judged by the investigator that entering the trial may be detrimental to the patient
9. Current treatment with systemic corticosteroids
10. History of prostatectomy due to prostate cancer, including nerve-sparing techniques
11. Use of alpha blockers or nitrates within 4 weeks prior to the screening visit
12. Use of PDE-5 inhibitor, or other treatments for erectile dysfunction within the last 4 weeks prior to the screening visit
13. Sexual partner is a pregnant or lactating female or a female with childbearing potential not taking reliable contraceptive methods during study period Note: Acceptable contraceptive forms include
1. Established use of oral, injected or implanted hormonal methods of contraception
2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
14. ED due to structural abnormality of the penis
15. With a history of HIV infection Note: HIV = Human Immunodeficiency Virus
16. Subject who has prolongation of QT interval \>500 ms (long QT syndrome)
17. Any of the following hematologic abnormalities:
1. Hemoglobin \< 10.0 g/dL
2. ANC \< 1,500/μL,
3. Platelets \< 75,000 /μL
18. Any of the following serum chemistry abnormalities:
1. Total bilirubin \> 1.5 × ULN,
2. gamma-GT \> 2.5 x ULN,
3. Alk-P \> 2.5 x ULN,
4. Serum albumin \< 3.0 g/dL, e Any other ≥ Grade 2 laboratory abnormality (based on CTCAE) at Screening visit (other than those listed above)
19. History of orthostatic hypotension Note: Orthostatic hypotension is defined as a decrease in systolic blood pressure of 20 mm Hg or a decrease in diastolic blood pressure of 10 mm Hg
20. History of syncope
21. Hereditary degenerative retinal disorders
22. History of loss of vision because of NAION (Non-arteritic anterior ischemic optic neuropathy), temporary or permanent loss of vision
23. Skin diseases, infection or cuts in penile area
24. History of psychiatric disorder
25. History of spinal cord injury
26. Use of HIV protease inhibitors (strong cytochrome P450 CYP3A4 inhibitors), such as indinavir or ritonavir, within 2 weeks prior to the screening visit
27. History of left ventricular outflow obstruction, such as aortic stenosis and hypertrophic cardiomyopathy
28. With any cardiovascular disorder that is not suitable for sexual activities.
29. Use of antiarrhythmic agents class IA (such as quinidine, or procainamide) and class III (such as amiodarone or sotalol), within 2 weeks prior to the screening visit
30. With priapism, such as sickle cell anemia, multiple myeloma or leukemia
20 Years
70 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
A2 Healthcare Taiwan Corporation
INDUSTRY
Tritech Biopharmaceuticals Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mackay Memorial Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Wei-Kung Tsai
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TR399
Identifier Type: -
Identifier Source: org_study_id